Patents Assigned to CHINOOK THERAPEUTICS, INC.
  • Methods of improving renal function
    Patent number: 11491137
    Abstract: Provided herein are methods of improving kidney function in a subject in need thereof.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: November 8, 2022
    Assignee: Chinook Therapeutics, Inc.
    Inventors: Philip Thomas Frohlich, Andrew James King, Chidambaram Ramachandran, Sarah Beth Noonberg
  • METHODS OF TREATING IgA NEPHROPATHY WITH AN APRIL BINDING ANTIBODY
    Publication number: 20210379183
    Abstract: Formulation and use of antibodies which bind human APRIL for the treatment of conditions related to IgA overproduction or deposition, including IgA Nephropathy.
    Type: Application
    Filed: May 28, 2021
    Publication date: December 9, 2021
    Applicants: CHINOOK THERAPEUTICS, INC., ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Teun VAN DE LAAR, Somayeh HONARMAND, John DULOS, Eduard DE COCK
  • Locked nucleic acid cyclic dinucleotide compounds and uses thereof
    Patent number: 11098077
    Abstract: The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the LNA-CDNs of the present invention are provided in the form of a composition comprising one or more cyclic dinucleotides that induce human STING-dependent type I interferon production, wherein the cyclic dinucleotides present in the composition have at least one 2?, 4? locked nucleic acids within the cyclic dinucleotide.
    Type: Grant
    Filed: July 1, 2017
    Date of Patent: August 24, 2021
    Assignees: CHINOOK THERAPEUTICS, INC., NOVARTIS AG
    Inventors: David Braun Kanne, Chudi Obioma Ndubaku, Jacob Robert Bruml, Thanh Ngoc Lan Le, Jeffrey McKenna, George Scott Tria, Stephen Canham
  • Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling
    Patent number: 11040053
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5? CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: June 22, 2021
    Assignee: CHINOOK THERAPEUTICS, INC.
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
  • Bis 2?-5?-RR-(3?F-A)(3?F-A) cyclic dinucleotide compound and uses thereof
    Patent number: 10975114
    Abstract: The present invention provides the cyclic dinucleotide compound 2?2?-RR-(3?F-A)(3?F-A) as a highly active immune stimulator that activates DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes), and compositions and uses thereof.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: April 13, 2021
    Assignees: CHINOOK THERAPEUTICS, INC., NOVARTIS AG
    Inventors: Justin Leong, Chudi Obioma Ndubaku, Jeffrey McKenna
  • Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
    Patent number: 10906930
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?- or 3?-mono-fluoro substituted, or 2?3?-di-fluoro substituted mixed linkage 2?,5?-3?,5? CDNs.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: February 2, 2021
    Assignees: CHINOOK THERAPEUTICS, INC., NOVARTIS AG
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr., Jeffrey McKenna, Stephen M. Canham, Chudi Obioma Ndubaku